The Efficacy and Safety of Travoprost, 0.004% Versus Tafluprost, 0.0015% in Primary Open-Angle Glaucoma or Ocular Hypertensive Patients

NCT00966940 Phase 4 COMPLETED Results posted

The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.

Details

Lead sponsor	Alcon Research
Phase	Phase 4
Status	COMPLETED
Enrolment	51
Start date	2009-09
Completion	2010-03

Conditions

• Glaucoma

Interventions

• Travoprost 0.004% ophthalmic solution (TRAVATAN)
• Tafluprost 0.0015% ophthalmic solution

Primary outcomes

• Mean Intraocular Pressure (IOP) at 8:00 PM — 6 weeks
  Intraocular pressure was measured by Goldmann applanation tonometry.